title: Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device.
abstract: The necessity for bone marrow aspiration and the lack of highly sensitive assays to detect residual disease present challenges for effective management of multiple myeloma (MM), a plasma cell cancer. We show that a microfluidic cell capture based on CD138 antigen, which is highly expressed on plasma cells, permits quantitation of rare circulating plasma cells (CPCs) in blood and subsequent fluorescence-based assays. The microfluidic device is based on a herringbone channel design, and exhibits an estimated cell capture efficiency of ~40-70%, permitting detection of <10 CPCs/mL using 1-mL sample volumes, which is difficult using existing techniques. In bone marrow samples, the microfluidic-based plasma cell counts exhibited excellent correlation with flow cytometry analysis. In peripheral blood samples, the device detected a baseline of 2-5 CD138+cells/mL in healthy donor blood, with significantly higher numbers in blood samples of MM patients in remission (20-24 CD138+cells/mL), and yet higher numbers in MM patients exhibiting disease (45-184 CD138+cells/mL). Analysis of CPCs isolated using the device was consistent with serum immunoglobulin assays that are commonly used in MM diagnostics. These results indicate the potential of CD138-based microfluidic CPC capture as a useful 'liquid biopsy' that may complement or partially replace bone marrow aspiration.
authors.affiliation: Division of Engineering, New York University Abu Dhabi, Abu Dhabi, UAE.|Mechanical and Aerospace Engineering Department, New York University, Brooklyn, NY 11201, USA.|Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
authors.forename: Mohammad A
authors.initials: MA
authors.lastname: Qasaimeh
authors.affiliation: Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
authors.forename: Yichao C
authors.initials: YC
authors.lastname: Wu
authors.affiliation: Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
authors.forename: Suman
authors.initials: S
authors.lastname: Bose
authors.affiliation: Division of Engineering, New York University Abu Dhabi, Abu Dhabi, UAE.
authors.forename: Anoop
authors.initials: A
authors.lastname: Menachery
authors.affiliation: VA Boston Healthcare System, Boston, MA, USA.|Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: Srikanth
authors.initials: S
authors.lastname: Talluri
authors.affiliation: VA Boston Healthcare System, Boston, MA, USA.
authors.forename: Gabriel
authors.initials: G
authors.lastname: Gonzalez
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: Mariateresa
authors.initials: M
authors.lastname: Fulciniti
authors.affiliation: Division of BioEngineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Harvard Stem Cell Institute, Harvard-MIT Division of Health Sciences and Technology, 65 Landsdowne St., Cambridge, MA 02139, USA.
authors.forename: Jeffrey M
authors.initials: JM
authors.lastname: Karp
authors.affiliation: VA Boston Healthcare System, Boston, MA, USA.|Dana-Farber Cancer Institute, Boston, MA, USA.|Brigham and Women's Hospital, Boston, MA, USA.|Harvard Medical School, Boston, MA, USA.
authors.forename: Rao H
authors.initials: RH
authors.lastname: Prabhala
authors.affiliation: Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
authors.forename: Rohit
authors.initials: R
authors.lastname: Karnik
mesh_terms: D000906:Antibodies / Q000378:metabolism*; D001853:Bone Marrow / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D006801:Humans; D056656:Lab-On-A-Chip Devices; D009101:Multiple Myeloma / Q000378:metabolism / Q000473:pathology*; D010950:Plasma Cells / Q000166:cytology*; D053668:Syndecan-1 / Q000378:metabolism*
chemical_list: D000906:Antibodies; D053668:Syndecan-1